The cost of relapse and the predictors of relapse in the treatment of schizophrenia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To assess the direct cost of relapse and the predictors of relapse during the treatment of patients with schizophrenia in the United States. METHODS: Data were drawn from a prospective, observational, noninterventional study of schizophrenia in the United States (US-SCAP) conducted between 7/1997 and 9/2003. Patients with and without relapse in the prior 6 months were compared on total direct mental health costs and cost components in the following year using propensity score matching method. Baseline predictors of subsequent relapse were also assessed. RESULTS: Of 1,557 participants with eligible data, 310 (20%) relapsed during the 6 months prior to the 1-year study period. Costs for patients with prior relapse were about 3 times the costs for patients without prior relapse. Relapse was associated with higher costs for inpatient services as well as for outpatient services and medication. Patients with prior relapse were younger and had onset of illness at earlier ages, poorer medication adherence, more severe symptoms, a higher prevalence of substance use disorder, and worse functional status. Inpatient costs for patients with a relapse during both the prior 6 months and the follow-up year were 5 times the costs for patients with relapse during the follow-up year only. Prior relapse was a robust predictor of subsequent relapse, above and beyond information about patients' functioning and symptom levels. CONCLUSIONS: Despite the historical decline in utilization of psychiatric inpatient services, relapse remains an important predictor of subsequent relapse and treatment costs for persons with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · cited 5×
“Compared to patients without prior relapse who relapsed in the subsequent year (NR), the patients with both prior and subsequent relapse (RR) were significantly younger, had a psychiatric hospitalization in the year prior to study enrollment, had more severe symptoms on the PANSS and MADRS, had poorer physical health…”
MethodInfluentialA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 3×
“This analysis compared the total cost and cost components between patients with versus without relapse while adjusting for clinical and functional status as measured by the PANSS, MADRS, and SF12 (physical component score and mental component score) using propensity score estimation.”
MethodCost of disorders of the brain in Europe
Andlin‐Sobocki, P., Jönsson, B., Wittchen, H., & Olesen, J. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01202.x · Cited by 1,139
Cost of Relapse in Schizophrenia
Weiden, P. J., & Olfson, M. (1995) · Schizophrenia Bulletin · doi:10.1093/schbul/21.3.419 · Cited by 666
Weiden, P. J., Kozma, C., Grogg, A., & Locklear, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.8.886 · Cited by 621 · cited 1×
“Consistent with prior research [1-3,6,9,21,22], the current analysis also found relapsed patients to have a more complex illness profile, which is not only associated with more severe symptomatology but also substance use, legal involvement, lower level of functioning, and poorer medication adherence.”
ResultGilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603 · cited 9×
“Using prescription information in patient medical records, the MPR was calculated as the proportion of days with any antipsychotic medication.”
BackgroundMethodResultInfluentialAscher-Svanum, H., Faries, D. E., Zhu, B., Ernst, F. R., Swartz, M. S., & Swanson, J. W. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0317 · Cited by 485
Self-citationPharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission
Valenstein, M., Copeland, L. A., Blow, F. C., McCarthy, J. F., Zeber, J. E., Gillon, L., Bingham, C. R., & Stavenger, T. (2002) · Medical Care · doi:10.1097/00005650-200208000-00002 · Cited by 338
Relapse in schizophrenia: costs, clinical outcomes and quality of life
Almond, S., Knapp, M., Francois, C., Toumi, M., & Brugha, T. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.4.346 · Cited by 310
Resource-based relative values. An overview
Hsiao, W. C. (1988) · JAMA · doi:10.1001/jama.260.16.2347 · Cited by 287
Svarstad, B. L., Shireman, T. I., & Sweeney, J. K. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.6.805 · Cited by 281 · cited 3×
“Costs associated with treatment received consequent to relapse may account for the largest share of treatment costs in schizophrenia [1-4], which is one of the most expensive to treat psychiatric conditions [5].”
BackgroundMethodResultRosenheck, R. A., Leslie, D. L., Sindelar, J., Miller, E. A., Lin, H., Stroup, T. S., McEvoy, J., Davis, S. M., Keefe, R. S. E., Swartz, M., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2080 · Cited by 281
Adjusting capitation rates using objective health measures and prior utilization.
Newhouse, J. P., Manning, W. G., Keeler, E. B., & Sloss, E. M. (1989) · PubMed Central · Cited by 243
Sun, S. X., Liu, G. G., Christensen, D. B., & Fu, A. Z. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x226050 · Cited by 196
De Hert, M., & Peuskens, J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01388.x · Cited by 182
A Longitudinal Study of Medication Nonadherence and Hospitalization Risk in Schizophrenia
Law, M. R., Soumerai, S. B., Ross‐Degnan, D., & Adams, A. S. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0107 · Cited by 157
The equity impact of the universal coverage policy: Lessons from Thailand
Prakongsai, P., Limwattananon, S., & Tangcharoensathien, V. (2009) · Advances in Health Economics and Health Services Research · doi:10.1108/s0731-2199(2009)0000021006 · Cited by 143
Outpatient Antipsychotic Treatment and Inpatient Costs of Schizophrenia
Marcus, S. C., & Olfson, M. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm061 · Cited by 114
Understanding and addressing adherence issues in schizophrenia: from theory to practice.
Weiden, P. J. (2007) · PubMed · Cited by 102
Weiden, P. J., & Buckley, P. F. (2007) · PubMed · Cited by 92
Tunis, S. L., Faries, D. E., Nyhuis, A. W., Kinon, B. J., Ascher‐Svanum, H., & Aquila, R. (2005) · Value in Health · doi:10.1111/j.1524-4733.2006.00083.x · Cited by 61
Self-citationLehman, A. F., Postrado, L. T., Delahanty, J. C., Fischer, E. P., Johnstone, B. M., Russo, P. A., & Crown, W. H. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007001 · Cited by 37
Mental Health In The Medicare Part D Drug Benefit: A New Regulatory Model?
Donohue, J. M. (2006) · Health Affairs · doi:10.1377/hlthaff.25.3.707 · Cited by 36
D’Agostino (1998) · doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b
Cited by
Feasibility, Acceptability, and Preliminary Efficacy of a Smartphone Intervention for Schizophrenia
Ben-Zeev, D., Brenner, C. J., Begale, M., Duffecy, J., Mohr, D. C., & Mueser, K. T. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu033 · Cited by 493
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392
“8 times higher healthcare costs than those with no prior relapse (Ascher-Svanum et al., 2010).”
BackgroundInfluentialAge at onset and the outcomes of schizophrenia: A systematic review and meta‐analysis
Immonen, J., Jääskeläinen, E., Korpela, H., & Miettunen, J. (2017) · Early Intervention in Psychiatry · doi:10.1111/eip.12412 · Cited by 280
Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review
Olivares, J. M., Sermon, J., Hemels, M., & Schreiner, A. (2013) · Annals of General Psychiatry · doi:10.1186/1744-859x-12-32 · Cited by 270
“[7,27,29,34,38,43,63,67,75-81]; deliberate self-harm or violent behaviour, suicidal or homicidal ideation, arrest [18,23,27,43,49,50,57,65,66,71,74,82-84];”
BackgroundMethodInfluentialWang, R., Aung, M. S. H., Abdullah, S., Brian, R., Campbell, A. T., Choudhury, T., Hauser, M., Kane, J., Merrill, M., Scherer, E. A., et al. (2016) · Proceedings of the 2016 ACM International Joint Conference on Pervasive and Ubiquitous Computing · doi:10.1145/2971648.2971740 · Cited by 257
“It is well understood that observable behavioral precursors can manifest prior to a transition into relapse [2].”
Background
Metadata
- Authors
- Ascher-Svanum, H., Zhu, B., Faries, D. E., Salkever, D., Slade, E. P., Peng, X., & Conley, R. R.
- Venue
- BMC Psychiatry
- Published
- 2010-01-07
- Volume
- 10
- Issue
- 1
- Pages
- 2-2
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W1989209269
- Cited by
- 275
- References
- 24
- FWCI
- 14.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.